多年来，恶性淋巴瘤的治疗一直由许多具有心脏毒性的药物代表，特别是蒽环类药物、环磷酰胺和胸腔放疗。尽管它们已经在临床实践中应用了几十年，但心脏毒性的精确机制和有效的预防仍然是研究的一部分。在本文中，我们讨论了恶性淋巴瘤化疗方案中最常用的抗癌药物，重点关注心脏毒性的分子机制的新见解。在分子水平上理解毒性可能揭示了心脏保护支持治疗的可能靶点，或者优化当前的治疗方案。此外，我们还回顾了新型的特异性靶向治疗及其在心肌肿瘤学中的挑战。© 2023 Rihackova, Rihacek, Vyskocilova Valik and Elbl.

Treatment of malignant lymphoma has for years been represented by many cardiotoxic agents especially anthracyclines, cyclophosphamide, and thoracic irradiation. Although they are in clinical practice for decades, the precise mechanism of cardiotoxicity and effective prevention is still part of the research. At this article we discuss most routinely used anti-cancer drugs in chemotherapeutic regiments for malignant lymphoma with the focus on novel insight on molecular mechanisms of cardiotoxicity. Understanding toxicity at molecular levels may unveil possible targets of cardioprotective supportive therapy or optimization of current therapeutic protocols. Additionally, we review novel specific targeted therapy and its challenges in cardio-oncology.© 2023 Rihackova, Rihacek, Vyskocilova Valik and Elbl.